Mold Exposure as a Flare Amplifier in ME/CFS

By Cynthia Adinig

Key Findings and Summary

Environmental conditions do not simply surround chronic illness. They shape its stability, severity, and response to care. Among the most overlooked of these conditions is indoor mold exposure, a persistent environmental stressor that may worsen symptom burden in people living with myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and related infection-associated chronic conditions. ME/CFS is a multi-system illness often triggered by infection and marked by post-exertional worsening, neurological dysfunction, immune dysregulation, and autonomic instability. In this terrain, mold exposure is not a minor housing inconvenience. It is a biologically relevant environmental signal capable of compounding physiologic strain across multiple systems at once. Mold-contaminated indoor spaces can release spores, fragments, and microbial compounds that irritate respiratory pathways, activate inflammatory signaling, disrupt sleep, aggravate autonomic dysfunction, and increase the likelihood of flare activity in already vulnerable patients.

For many people living with ME/CFS, myself included, mold exposure may contribute to worsening fatigue, cognitive dysfunction, headaches, autonomic instability, respiratory irritation, and reduced functional capacity. What appears to be a sudden symptom crash may in many cases reflect the interaction between chronic illness and a destabilizing indoor environment. In that sense, mold is not just an exposure. It is part of the terrain shaping whether the body remains in relative equilibrium or is pushed into repeated instability.

This paper also advances a broader point: mold exposure may do more than worsen symptoms. It may suppress treatment response. The simulated 12-week low-dose naltrexone model presented here suggests that patients living in mold-exposed environments may reach earlier and lower treatment plateaus than comparable patients in non-mold settings, even when treatment conditions are otherwise held constant. This raises an important clinical and policy concern. Some patients who appear poorly responsive to therapy may in fact be environmentally constrained rather than truly treatment refractory.

This matters beyond individual symptom management. Mold exposure sits at the intersection of housing quality, environmental health, disability burden, healthcare utilization, and chronic disease policy. As the population living with infection-associated chronic conditions continues to grow, understanding how indoor environmental exposures shape disease stability and treatment outcomes will become increasingly important for public health planning, healthcare utilization forecasting, housing intervention strategy, and long-term economic modeling. Recognizing mold as part of the broader illness terrain helps move the conversation from anecdote to infrastructure, and from symptom management alone to the conditions required for recovery to become possible.

Introduction

Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is a chronic, multi-system illness characterized by severe fatigue, post-exertional symptom worsening, cognitive dysfunction, autonomic instability, and immune dysregulation. The disease is frequently triggered by infection and is increasingly recognized as part of a broader category of infection-associated chronic conditions (IACCs), which also includes illnesses such as Long COVID and certain post-viral dysautonomia syndromes.

Traditional surveillance systems have historically underestimated the scale of ME/CFS. Using CYNAERA’s corrected prevalence modeling, which maps ME/CFS phenotypes across post-viral illness populations including Long COVID, the number of Americans living with ME/CFS-equivalent illness may fall between 15 and 23 million individuals, with broader phenotype mapping suggesting 20 to 30 million people may experience ME/CFS-like post-viral illness patterns within the larger infection-associated chronic condition population (Adinig 2026). These estimates suggest that ME/CFS and related post-infectious illness patterns represent a substantial and under-recognized public health burden. A defining feature of ME/CFS is the presence of post-exertional malaise (PEM), a phenomenon in which physical or cognitive activity leads to delayed worsening of symptoms. However, many patients report that symptom flares are not triggered solely by exertion. Environmental exposures, including air pollution, chemical irritants, temperature changes, and indoor environmental contaminants, are frequently associated with disease instability.

Among these environmental factors, mold exposure has received increasing attention due to its potential to affect immune function, respiratory health, and neurological processes. Indoor mold growth commonly occurs in buildings affected by water damage, flooding, plumbing leaks, or persistent humidity. Mold spores and related microbial products can act as biological irritants that influence inflammatory pathways and immune signaling (Institute of Medicine 2004; Mendell et al. 2011). For individuals with underlying immune dysregulation, autonomic instability, and inflammatory vulnerability, such exposures may produce disproportionate physiological responses. Understanding how indoor environmental conditions interact with chronic illness stability is therefore an important step in addressing the broader health burden associated with infection-associated chronic conditions.

Mold Exposure and Indoor Environmental Risk

Mold growth occurs when moisture accumulates within indoor environments such as basements, bathrooms, wall cavities, insulation, HVAC systems, or building materials affected by flooding, plumbing leaks, roof failures, or persistent humidity. Buildings with inadequate ventilation, unresolved water intrusion, or poorly maintained infrastructure are particularly vulnerable to these conditions. When mold colonies develop, they release microscopic spores, fungal fragments, and biologically active compounds into the air that can be inhaled by occupants.

In addition to spores, mold-contaminated environments may release microbial volatile organic compounds (MVOCs) and other biologically active particles associated with fungal metabolism. These compounds contribute to the characteristic musty odor frequently reported in water-damaged buildings and are widely recognized indicators of microbial growth within indoor environments (World Health Organization 2009).

A substantial body of environmental health research has documented the relationship between damp indoor environments, mold growth, and adverse health outcomes. Major reviews conducted by the National Academies of Sciences and the World Health Organization have concluded that exposure to damp or mold-contaminated indoor environments is associated with respiratory symptoms, asthma exacerbation, allergic responses, cough, wheezing, and upper respiratory irritation (Institute of Medicine 2004; World Health Organization 2009). Large epidemiological reviews have similarly found consistent associations between damp indoor environments and increased rates of respiratory illness and asthma among building occupants (Fisk et al. 2007; Mendell et al. 2011).

Importantly, indoor mold contamination is rarely an isolated environmental event. It is typically a signal of underlying structural or maintenance failures within a building. Persistent moisture intrusion, plumbing leaks, flooding, condensation, or inadequate ventilation create conditions that allow mold to colonize drywall, insulation, wood framing, carpets, and HVAC systems. Because mold growth frequently occurs within wall cavities or building materials, contamination may remain present even when visible mold appears limited.

Public health guidance consistently identifies moisture control and proper building maintenance as the primary methods of mold prevention. Persistent indoor mold growth therefore often reflects unresolved water damage, ventilation failures, or structural moisture problems within the built environment rather than occupant behavior (Institute of Medicine 2004; World Health Organization 2009). When these conditions are not promptly addressed, microbial growth can spread through building materials and indoor air systems, increasing exposure risk for occupants.

For individuals living with chronic illnesses involving immune dysregulation or inflammatory instability, these environmental exposures can have amplified physiological effects. Many people living with ME/CFS report experiencing worsening fatigue, neurological symptoms, respiratory irritation, headaches, and autonomic instability when exposed to mold-contaminated indoor environments. Patient communities and clinical advocates frequently document repeated symptom destabilization linked to water-damaged or mold-contaminated housing conditions.

These reports are consistent with the known biological vulnerabilities associated with ME/CFS, including immune dysregulation, neuroinflammation, and impaired cellular energy metabolism (Komaroff and Bateman 2021; Nacul et al. 2020). Environmental irritants capable of activating inflammatory pathways may therefore place additional strain on already dysregulated physiological systems.

Because moisture-driven mold contamination is typically preventable through timely maintenance and remediation, damp indoor environments are widely recognized as both a housing quality issue and a public health concern. Addressing mold exposure therefore requires attention not only to individual medical care but also to the structural conditions of the built environment that allow these exposures to occur.

Biological Pathways Relevant to ME/CFS

Several biological mechanisms may explain why mold exposure could worsen symptoms in people living with ME/CFS. First, mold spores and fragments can activate immune responses in the respiratory tract. In susceptible individuals, this may lead to inflammatory signaling that contributes to systemic immune activation. Second, microbial toxins and volatile compounds produced by certain mold species may affect neurological signaling. These compounds can irritate mucosal surfaces and may influence the central nervous system through inflammatory pathways. Third, environmental mold exposure may worsen respiratory symptoms, which can further reduce oxygen delivery and increase physiological stress in individuals already experiencing autonomic dysfunction.

ME/CFS research has documented abnormalities in immune regulation, autonomic nervous system function, and energy metabolism (Komaroff and Bateman 2021). Environmental exposures that stimulate inflammatory pathways may therefore contribute to symptom worsening in vulnerable patients.

Mold Exposure and Symptom Flares

People living with ME/CFS frequently report increased symptom severity following exposure to mold-contaminated environments. While patient reports alone cannot establish causation, they provide important signals that can guide further research into environmental drivers of disease instability. Mold exposure introduces a range of biological irritants into indoor environments, including spores, fungal fragments, and microbial volatile organic compounds that can affect respiratory pathways and immune signaling (Mendell et al. 2011; Fisk et al. 2007).

These exposures can provoke inflammatory responses in susceptible individuals. Studies examining damp indoor environments have consistently demonstrated associations between mold exposure and respiratory illness, asthma exacerbation, neurological irritation, and fatigue-related symptoms (Institute of Medicine 2004; World Health Organization 2009; Mendell et al. 2011). Because ME/CFS involves abnormalities in immune regulation, autonomic nervous system signaling, and cellular energy metabolism, environmental stressors may place additional strain on already dysregulated biological systems (Komaroff and Bateman 2021; Nacul et al. 2020). For individuals living with ME/CFS, mold exposure may therefore contribute to symptom destabilization that manifests as increased fatigue, cognitive dysfunction, headaches, respiratory irritation, and autonomic instability. Environmental instability in this context may function as a flare amplifier rather than a primary disease cause, worsening disease expression and increasing the likelihood of symptom crashes in individuals who already have the condition (Jason et al. 2015; Chu et al. 2019).

Using CYNAERA’s corrected prevalence framework, the potential scale of this environmental interaction becomes clearer. Current modeling suggests that approximately 15–23 million Americans may be living with ME/CFS-equivalent illness when post-viral phenotypes across Long COVID are mapped using updated prevalence correction methods. Housing research indicates that 10–20 percent of homes contain significant dampness or mold-related indoor air risks (Institute of Medicine 2004; WHO 2009; Mendell et al. 2011). Applying these environmental exposure estimates to the corrected ME/CFS population suggests that roughly 1.5 to 4.6 million Americans with ME/CFS may currently live in environments capable of amplifying disease instability. This reframes mold exposure as more than an individual housing problem. It becomes a population-scale environmental modifier of chronic illness burden.

Housing Conditions and Public Health Implications

Indoor mold exposure is rarely a random event. It is typically the downstream result of structural failure. Water intrusion, poor ventilation, aging infrastructure, flood damage, and persistent humidity create the conditions in which mold becomes embedded in walls, ceilings, ducts, and living spaces. In this sense, mold is not merely an environmental trigger but a built-environment signal that housing conditions are failing to protect health.

Population housing research suggests that 10–20 percent of homes contain significant dampness or mold-related indoor air risks, particularly in regions with humidity, aging infrastructure, or prior water intrusion events (Institute of Medicine 2004; World Health Organization 2009; Mendell et al. 2011). When this environmental exposure rate is applied to CYNAERA’s corrected ME/CFS prevalence estimates of approximately 15–23 million Americans living with ME/CFS-equivalent illness, the number of patients potentially residing in mold-risk housing environments may fall between 1.5 and 4.6 million individuals (Adinig 2026). Environmental instability in these settings may amplify symptom crashes in patients with immune dysregulation, autonomic dysfunction, and neuroinflammatory illness patterns that characterize ME/CFS (Komaroff and Bateman 2021; Nacul et al. 2020). Prior research has shown that severe symptom exacerbations in ME/CFS populations can lead to emergency department visits related to dysautonomia episodes, respiratory distress, migraine crises, and post-exertional malaise collapse events (Jason et al. 2008; Chu et al. 2019).

Applying a conservative instability assumption that 10–20 percent of mold-exposed patients experience one additional urgent care or emergency visit annually due to environmentally amplified symptom crashes, CYNAERA modeling suggests that mold-related housing instability could contribute to approximately 150,000 to 920,000 additional urgent care or emergency department visits per year within the ME/CFS population (Adinig 2026).

This estimate does not claim that mold exposure directly causes these medical events. Instead, it illustrates how environmental instability layered onto large chronic illness populations can translate into measurable healthcare system strain. Even modest environmental multipliers can produce substantial increases in emergency care demand when applied across millions of medically vulnerable individuals. For public health planning, this reframes mold-contaminated housing from a narrow environmental concern into a chronic illness destabilization factor embedded within the built environment. When structural housing failures interact with infection-associated chronic conditions, the resulting health burden may manifest not only as worsening symptoms but also as increased disability burden, healthcare utilization, and economic loss across affected populations.

Environmental Modeling of Mold Exposure Risk

Understanding mold as a potential trigger for symptom instability requires more than describing exposure. It requires a way to model how environmental conditions translate into biological stress for people living with ME/CFS and related infection-associated chronic conditions. Indoor mold growth is not a static hazard. It fluctuates with humidity, temperature, building ventilation, water intrusion events, and seasonal spore cycles. These environmental dynamics can create changing exposure patterns that may interact with the immune, autonomic, and neurological vulnerabilities already present in ME/CFS.

To illustrate how these dynamics may be analyzed, this paper references simplified modeling concepts from the VitalGuard™ environmental monitoring framework developed by the CYNAERA Institute. VitalGuard integrates environmental signals, housing risk indicators, and condition-specific sensitivities to estimate how changes in environmental conditions may influence symptom stability in vulnerable populations. The public-facing formulas presented below represent web-safe conceptual summaries designed for research discussion and environmental health modeling. Exact coefficients and calibration methods used in licensed implementations remain proprietary.

Within the context of mold exposure, the framework focuses on how moisture conditions, building characteristics, and seasonal environmental patterns combine to influence indoor mold burden and potential health impact.

Environmental Mold Risk Modeling Using the VitalGuard™ Framework

Environmental triggers can influence symptom stability in individuals living with ME/CFS and related infection-associated chronic conditions. To illustrate how indoor environmental factors may contribute to flare instability, this paper references simplified modeling concepts derived from the VitalGuard™ environmental monitoring framework. The following formulas represent public, web-safe summaries used for explanatory and research discussion purposes. Exact proprietary coefficients used in licensed CYNAERA systems are not disclosed.

Mold Environmental Burden Index (MEBI)

Purpose: summarize daily mold-related environmental burden relevant to ME/CFS.

Formula

MEBI(t) = Σ [ Mi(t) × Wi ]

Where

• Mi(t) represents the intensity of mold-related environmental signals at time t. These signals may include indoor humidity, recent flooding or water damage events, seasonal mold spore counts, and microbial volatile organic compound levels when available.

• Wi represents sensitivity weights reflecting known biological vulnerability to mold exposure in populations with immune dysregulation, mast cell activation, or chronic inflammatory illness.

The Mold Environmental Burden Index allows environmental monitoring systems to summarize multiple mold-related signals into a single interpretable value representing potential physiological stress on susceptible individuals.

Mold-Adjusted Flare Instability Score

Purpose: estimate environmental contributions to symptom destabilization in ME/CFS.

Formula

Flare_Instability(t) = Σ [ Mi(t) × Wi(c) × R(g) × S(season) ] + H(t) + I(t)

Where

• Mi(t) represents mold-related environmental signals such as indoor humidity, mold spore levels, or water damage risk.

• Wi(c) represents condition-specific sensitivity weights for ME/CFS and related infection-associated chronic conditions. Evidence suggests individuals with autonomic dysfunction, mast cell activation, or neuroinflammatory disease may exhibit heightened responses to environmental irritants.

• R(g) represents regional vulnerability modifiers reflecting housing conditions, building age, ventilation characteristics, and local climate patterns associated with increased mold risk.

• S(season) represents seasonal multipliers reflecting known patterns of mold proliferation, including increased humidity, rainfall events, and seasonal spore blooms.

• H(t) represents housing-specific exposure conditions such as HVAC malfunction, water intrusion, or structural moisture accumulation.

• I(t) represents interaction effects between mold exposure and other environmental stressors including particulate matter, wildfire smoke, or chemical irritants.

Together these factors approximate how indoor environmental instability may amplify symptom flares in susceptible populations.

VitalGuard-MoldX™ Indoor Mold Risk Signal

Purpose: estimate mold-specific exposure risk within residential environments.

Formula

MoldX(t) = Mold_Index(t) × Housing_Risk × Sensitivity_Mold

Where

• Mold_Index(t) represents environmental indicators associated with mold proliferation such as humidity levels, flooding events, persistent moisture conditions, or regional spore monitoring data.

• Housing_Risk reflects structural vulnerability including building age, ventilation quality, water damage history, and insulation or moisture barrier conditions.

• Sensitivity_Mold represents patient-level susceptibility, which may vary depending on immune function, mast cell activation, respiratory disease, or prior mold exposure history.

The MoldX signal allows environmental monitoring systems to isolate mold-specific exposure risk within broader environmental monitoring models.

Indoor Particulate and Mold Fragment Burden

Indoor air in mold-contaminated buildings often contains fungal fragments and spores that behave similarly to particulate matter. To estimate the contribution of these particles to indoor exposure environments, VitalGuard modeling incorporates particulate crossover estimates.

Formula

Indoor_Particle_Load(t) = Outdoor_PM(t) × Crossover_Rate × Indoor_Load_Factor

This formulation approximates how outdoor particulate matter and indoor biological particles may accumulate within poorly ventilated environments, increasing respiratory and inflammatory burden.

Mold-Driven Flare Forecasting

Environmental forecasting can be used to estimate how upcoming weather or humidity changes may influence mold growth and exposure conditions.

Formula

Flare_Risk(t+1) = [ Environmental_Shift × Mold_Sensitivity × Symptom_Pattern ] × Regional_Modifier

Where

• Environmental_Shift represents forecast changes in humidity, rainfall, or temperature that may accelerate mold growth.

• Mold_Sensitivity reflects individual susceptibility to mold exposure.

• Symptom_Pattern represents similarity between current symptoms and previously observed flare patterns.

• Regional_Modifier incorporates geographic differences in housing structure, climate, and environmental exposure patterns.

Together these variables allow environmental monitoring systems to estimate whether upcoming environmental conditions may increase the probability of symptom flares in individuals living with ME/CFS.

The VitalGuard™ framework, including MoldX and associated indices, has been deployed and validated across multiple real-world settings. Case studies documenting framework performance include:

• Journal My Health Integration: Symptom pattern recognition and clinical intelligence layer (CYNAERA Case Studies, 2025)

• 24-Hour Adrenal Crisis Architecture: Rapid deployment for PCORI Convening Award preparation (CYNAERA Case Studies, 2025)

• Pharma-Grade Tolerability Framework: MCAS-informed formulation design for post-viral populations (CYNAERA Case Studies, 2025)

These deployments demonstrate the operational viability of CYNAERA's environmental modeling and patient-terrain intelligence across clinical, research, and pharmaceutical contexts. For detailed validation methodology, economic outcome analysis, and module-specific performance data, see CYNAERA Case Studies: Operational Proof Across Clinical Systems, Policy, and Infrastructure (available at cynaera.com/case-studies).

Simulated LDN Response in ME/CFS With and Without Mold Exposure

To illustrate how housing-related mold burden may alter apparent treatment response in ME/CFS, a simplified four-patient simulation was constructed using matched low-dose naltrexone conditions across two levels of illness severity and two housing exposure conditions. Two hypothetical patients were modeled with mild-moderate and severe ME/CFS in non-mold environments, and two parallel patients were modeled under mold-exposed housing conditions. All patients received the same LDN protocol over the same observation period, with adherence, pacing guidance, follow-up interval, and supportive care assumptions held constant. The purpose of the simulation was not to estimate exact clinical effect sizes, but to demonstrate how environmental burden may compress therapeutic gain and produce an earlier treatment plateau despite identical pharmacologic input.

Housing-related mold burden was modeled using VitalGuard-MoldX™, which estimates mold-triggered flare risk as a function of mold level, housing condition, and patient sensitivity. Simulated treatment response was modeled using the LongCOVID-LDN Response Tracker, applied here to ME/CFS due to substantial overlap in neuroimmune symptom domains including fatigue, PEM, sleep disturbance, and sensory and cognitive instability. For this vignette, mold exposure was treated as an environmental suppressor of therapeutic gain rather than as a change in the treatment itself.

The core mold exposure formula used was:

MoldX Score = Mold Index × Housing Condition × Sensitivity Index.

The treatment response framework was derived from the LDN tracker formula:

ReliefIndex = SymptomImprovementPercent × Duration − SideEffectMentions × SideEffectSeverity.

These formulas are presented as high-level interpretive frameworks for simulation and do not represent a validated clinical dosing algorithm or a complete proprietary implementation.

To interpret environmental suppression more clearly, higher MoldX burden was modeled as reducing the durability and plateau height of symptom improvement over time. Four matched hypothetical patients were included. Patient A represented mild-moderate ME/CFS in a non-mold environment. Patient B represented mild-moderate ME/CFS in a mold-exposed environment. Patient C represented severe ME/CFS in a non-mold environment. Patient D represented severe ME/CFS in a mold-exposed environment. All four patients were assumed to have the same access to treatment, identical LDN titration, equivalent adherence, and comparable non-environmental background supports. Only illness severity and mold exposure status varied across the simulation.

For the exposure model, non-mold housing conditions were assigned low Mold Index and lower housing risk values, while mold-exposed housing conditions were assigned elevated Mold Index and housing risk values. Sensitivity Index was increased modestly in severe ME/CFS to reflect greater physiologic fragility and lower tolerance for ongoing inflammatory burden. This produced the expected gradient in MoldX burden, with the lowest exposure score in the mild-moderate non-mold condition and the highest in the severe mold-exposed condition. The model assumes that greater mold burden contributes to more frequent flare activity, prolonged PEM recovery, poorer sleep stabilization, and reduced conversion of early symptom relief into durable functional gain.

Simulated Patient Conditions and Modeled Exposure Burden Table

Patient	ME/CFS Severity	Housing Condition	Mold Index	Housing Condition Value	Sensitivity Index	MoldX Score
A	Mild-Moderate	Non-Mold	0.5	0.8	1.0	0.40
B	Mild-Moderate	Mold-Exposed	1.5	1.4	1.0	2.10
C	Severe	Non-Mold	0.5	0.8	1.3	0.52
D	Severe	Mold-Exposed	1.5	1.4	1.3	2.73

Treatment response was then simulated across a 12-week LDN observation period. Mild-moderate, non-mold patients were modeled as having the highest percentage improvement and the latest plateau, reflecting the greatest ability to consolidate therapeutic benefit under relatively stable environmental conditions. Mild-moderate patients in mold-exposed housing were modeled as showing partial initial improvement, followed by earlier flattening of gains and greater symptom volatility. Severe ME/CFS patients in non-mold housing were modeled as improving more slowly than mild-moderate patients, but still achieving meaningful benefit over time. Severe patients in mold-exposed housing were modeled as demonstrating the lowest cumulative response, the earliest plateau, and the highest likelihood of appearing treatment resistant despite receiving the same therapeutic protocol.

Simulated 12-Week LDN Response by Severity and Mold Exposure Table

Patient	ME/CFS Severity	Housing Condition	Week 12 Symptom Improvement	Side Effect Burden	ReliefIndex	Plateau Timing
A	Mild-Moderate	Non-Mold	24%	2	286	Late
B	Mild-Moderate	Mold-Exposed	11%	3	129	Early
C	Severe	Non-Mold	15%	3	177	Mid
D	Severe	Mold-Exposed	4%	4	44	Earliest

In this simulation, the strongest overall response occurred in the mild-moderate non-mold condition, followed by the severe non-mold condition. Mold exposure blunted response at both severity levels. The mild-moderate mold-exposed patient achieved less than half the simulated symptom improvement of the matched non-mold patient and reached plateau earlier in the treatment window. The severe mold-exposed patient showed the smallest overall gain and the lowest final Relief Index, suggesting that persistent environmental burden may sharply reduce the amount of pharmacologic benefit converted into stable clinical improvement.

These findings support the hypothesis that mold exposure may not only worsen symptoms directly, but may also suppress the visible effectiveness of otherwise reasonable therapeutic interventions in ME/CFS. The plateau effect is especially important in interpreting apparent treatment failure. In this model, plateauing was defined as the point at which weekly symptom improvement flattened despite continued treatment. Patients in non-mold conditions continued to accumulate benefit longer, even when total gains remained partial. By contrast, mold-exposed patients reached a lower plateau sooner, with more instability during the treatment window. This creates a clinically important risk of misclassification, in which environmentally burdened patients may be labeled nonresponsive or refractory when the more accurate interpretation is that treatment response is being constrained by ongoing exposure.

Simulated 12-Week LDN Response in ME/CFS With and Without Mold Exposure

Simulated 12-week low-dose naltrexone response trajectories in mild-moderate and severe ME/CFS under non-mold and mold-exposed housing conditions. Non-mold conditions produced larger cumulative gains and later plateauing at both severity levels. Mold-exposed conditions were associated with blunted improvement, earlier plateau formation, and lower total Relief Index despite identical treatment assumptions.

Other Environmental Pollutants That May Trigger ME/CFS Flares

Mold exposure is only one of several environmental factors that may contribute to symptom destabilization in people living with ME/CFS and related infection-associated chronic conditions. A growing body of environmental health research shows that several common air pollutants can activate inflammatory pathways, increase oxidative stress, and disrupt autonomic regulation.

These biological effects overlap with core pathophysiologic features observed in ME/CFS, including mitochondrial dysfunction, neuroinflammation, and immune dysregulation (National Academies of Sciences, 2015; Komaroff & Lipkin, 2021). Although research specifically examining pollutant exposure in ME/CFS populations remains limited, the mechanistic overlap between environmental toxicology and chronic illness biology suggests that certain pollutants may act as flare amplifiers in vulnerable individuals.

Polycyclic Aromatic Hydrocarbons (PAHs)

Polycyclic aromatic hydrocarbons are produced during incomplete combustion and are commonly found in diesel exhaust, coal emissions, wildfire smoke, tobacco smoke, and charred foods. These compounds can activate the aryl hydrocarbon receptor (AhR), a signaling pathway involved in immune regulation and inflammatory responses (Boström et al., 2002; Kim et al., 2013).

Activation of AhR signaling has been associated with cytokine imbalance, mitochondrial oxidative stress, and endocrine interference, biological mechanisms that overlap with pathways implicated in chronic inflammatory illnesses (ATSDR, 2020; IARC, 2010). Environmental spikes in PAH-rich smoke, particularly during wildfire events or in high-traffic corridors, are frequently associated with increased neurological and respiratory symptoms in exposed populations.

Fine and Coarse Particulate Matter (PM₂.₅ and PM₁₀)

Particulate matter refers to microscopic particles suspended in air that originate from traffic emissions, industrial activity, biomass burning, construction dust, and wildfire smoke. Fine particles (PM₂.₅) are particularly concerning because they can penetrate deep into lung tissue and enter the bloodstream.

Exposure to particulate pollution has been linked to systemic inflammation, oxidative stress, endothelial dysfunction, and autonomic nervous system disruption. These effects are partly mediated through activation of inflammatory signaling pathways such as NF-κB and increases in circulating cytokines including IL-6 and TNF-α (Pope et al., 2016; Gawda et al., 2018). Because these pathways overlap with mechanisms proposed in ME/CFS pathophysiology, particulate exposure may contribute to symptom worsening in environmentally sensitive patients (World Health Organization, 2022; U.S. EPA, 2023).

Nitrogen Dioxide (NO₂)

Nitrogen dioxide is a traffic-dominant air pollutant produced primarily by vehicle emissions and fossil fuel combustion. Exposure to NO₂ is known to increase airway inflammation and impair immune cell function, particularly macrophage activity within the respiratory tract (Ciencewicki & Jaspers, 2007). These effects can increase vulnerability to respiratory irritation and systemic inflammatory responses, which may exacerbate fatigue and autonomic symptoms in individuals with chronic inflammatory conditions (World Health Organization, 2022; U.S. EPA, 2022).

Ground-Level Ozone (O₃)

Ground-level ozone forms through photochemical reactions between sunlight and pollutants emitted by vehicles and industrial sources. Ozone is a powerful oxidant capable of damaging airway epithelial cells and increasing systemic oxidative stress (Hollingsworth et al., 2007).

Elevated ozone exposure has been associated with respiratory inflammation, fatigue, and increased cardiovascular strain, particularly in populations with preexisting illness (Jerrett et al., 2009; U.S. EPA, 2023). Because oxidative stress and inflammatory signaling are central features of ME/CFS biology, ozone exposure may contribute to worsening symptom instability during high-pollution events.

Sulfur Dioxide (SO₂)

Sulfur dioxide is a combustion by-product generated by power plants, industrial processes, and certain fuel sources. SO₂ exposure can trigger bronchoconstriction and airway irritation and also contributes to the formation of secondary particulate pollution in the atmosphere (Chen et al., 2007).

These respiratory and inflammatory effects may place additional stress on individuals living with chronic fatigue and autonomic instability, particularly during episodes of elevated regional pollution (World Health Organization, 2022; U.S. EPA, 2022).

Volatile Organic Compounds (VOCs)

Volatile organic compounds include a large group of airborne chemicals such as benzene, toluene, formaldehyde, acetaldehyde, xylenes, acrolein, and styrene. These compounds are emitted from traffic exhaust, industrial activity, building materials, and indoor sources such as paints, adhesives, and furniture off-gassing (U.S. EPA, 2022). Many VOCs have documented neurotoxic and inflammatory effects and may contribute to mast cell activation, autonomic instability, and respiratory irritation in sensitive individuals (ATSDR, 2020; Drzazga et al., 2021; Hanna et al., 2021). For patients with ME/CFS and overlapping conditions such as mast cell activation syndrome or chemical sensitivity, VOC exposure may contribute to headaches, cognitive dysfunction, and worsening fatigue.

Table: Environmental Pollutants Associated with ME/CFS Flare Instability

Environmental Trigger	Common Sources	Biological Mechanisms	Potential Symptom Effects in ME/CFS
Indoor Mold	Water damage, flooding, humidity, poor ventilation	Immune activation, mast cell signaling, inflammatory cytokines, respiratory irritation	Fatigue escalation, headaches, cognitive dysfunction, autonomic instability
Polycyclic Aromatic Hydrocarbons (PAHs)	Diesel exhaust, wildfire smoke, tobacco smoke, charred foods	Aryl hydrocarbon receptor activation, oxidative stress, mitochondrial disruption	Brain fog, headaches, fatigue worsening
Particulate Matter (PM₂.₅ / PM₁₀)	Traffic emissions, industrial pollution, wildfire smoke, construction dust	NF-κB inflammatory signaling, IL-6 and TNF-α elevation, oxidative stress	Post-exertional symptom worsening, respiratory irritation, fatigue
Nitrogen Dioxide (NO₂)	Vehicle emissions, fossil fuel combustion	Airway inflammation, impaired macrophage function	Respiratory irritation, increased fatigue
Ground-Level Ozone (O₃)	Photochemical smog, urban pollution	Oxidative stress, epithelial injury, systemic inflammatory response	Headaches, fatigue, breathing discomfort
Sulfur Dioxide (SO₂)	Power plants, industrial combustion	Bronchoconstriction, airway inflammation, particulate formation	Respiratory symptoms, fatigue
Volatile Organic Compounds (VOCs)	Building materials, paints, adhesives, furniture off-gassing, traffic emissions	Neurotoxicity, mast cell activation, autonomic disruption	Cognitive dysfunction, headaches, fatigue, chemical sensitivity

Mold Exposure and the Broader IACC Environmental Context

ME/CFS is increasingly recognized as part of a broader category of infection-associated chronic conditions (IACCs), a group of illnesses that emerge following infection and persist through long-term immune, neurological, or metabolic dysfunction. This category includes conditions such as Long COVID as well as other post-infectious syndromes characterized by chronic fatigue, dysautonomia, and neuroinflammation (National Academies of Sciences, Engineering, and Medicine 2024; Komaroff and Bateman 2021).

The emergence of Long COVID has dramatically expanded the population living with post-infectious chronic illness. Large epidemiological studies suggest that tens of millions of Americans may now be living with infection-associated chronic conditions triggered by SARS-CoV-2 infection (Xie et al. 2022; Al-Aly et al. 2021). As a result, environmental triggers that influence disease stability may affect a much larger population than previously recognized.

Environmental exposures such as mold contamination, air pollution, wildfire smoke, and temperature instability may therefore have broader implications for chronic illness management. Research examining environmental exposures and inflammatory disease suggests that environmental stressors can influence immune regulation and symptom severity in vulnerable populations (Landrigan et al. 2018; Schraufnagel et al. 2019). Understanding how environmental triggers interact with IACCs is essential for developing more effective prevention strategies and environmental health policies.

Economic Impact of Environmental Triggers in ME/CFS

Environmental triggers such as mold exposure do not only worsen symptoms. They increase strain across the entire chronic illness economy. When patients experience more frequent symptom crashes, the costs extend beyond temporary discomfort. They appear as additional medical visits, repeated diagnostic testing, medication adjustments, lost work capacity, caregiver burden, and greater long-term disability risk.

ME/CFS already carries substantial economic costs in the United States. Prior analyses have estimated national economic losses in the tens of billions of dollars annually when healthcare expenditures and lost productivity are combined (Jason et al. 2008; Collin et al. 2011). As corrected prevalence estimates suggest that 15–23 million Americans may now live with ME/CFS-equivalent illness, the economic implications of environmental destabilization become more significant (Adinig 2026). Earlier sections of this paper estimated that 1.5 to 4.6 million individuals with ME/CFS may reside in housing environments with elevated mold exposure risk. Applying a conservative assumption that 10–20 percent of these patients experience one additional urgent care or emergency department visit annually due to environmentally amplified symptom instability suggests that mold-related housing conditions could contribute to approximately 150,000 to 920,000 additional emergency or urgent care visits each year (Adinig 2026).

Using conservative national cost estimates of approximately $1,200–$2,500 per emergency department visit, this additional healthcare utilization alone could represent $225 million to $1.38 billion in annual emergency care costs attributable to environmentally amplified symptom instability within the ME/CFS population (AHRQ 2023; Healthcare Cost Institute 2022). These estimates capture only one portion of the broader economic burden. Environmental instability can also increase indirect costs through lost work productivity, extended recovery periods following symptom crashes, and increased reliance on caregivers or disability support. For patients living in damp or mold-contaminated housing environments, recovery becomes more difficult because the environment itself may continue to trigger physiological stress responses.

Housing-related mold exposure can also produce direct household economic shocks. Remediation costs, temporary relocation expenses, replacement of contaminated furniture or personal belongings, and legal disputes with landlords can impose substantial financial strain. For households already managing chronic illness, these expenses can compound the economic burden associated with long-term disease management. From a systems perspective, mold exposure functions as a health burden multiplier. It does not create the underlying illness but can increase the cost of managing it by destabilizing patients in the environments where recovery should occur. As infection-associated chronic conditions affect millions of people, environmental triggers embedded within housing infrastructure may contribute to significant and largely unrecognized healthcare and economic costs.

Policy Implications

The policy lesson is straightforward. Chronic illness cannot be managed fully at the level of medication and appointments alone if the built environment continues to destabilize the patient. Indoor mold contamination is typically addressed as a housing or maintenance problem, yet for people living with infection-associated chronic conditions it may also function as a chronic disease aggravator. Policies that improve moisture control, ventilation standards, building maintenance, and landlord accountability can therefore do more than improve housing quality. They may help reduce avoidable symptom flares in medically vulnerable populations. This is particularly important in regions facing flooding, extreme rainfall, aging infrastructure, or climate-driven humidity shifts, all of which increase the likelihood of damp indoor environments (IPCC 2023).

Public health planning should begin to treat environmental trigger reduction as part of chronic illness stabilization strategy. That includes stronger mold inspection and remediation pathways, housing protections for disabled tenants, and environmental health guidance tailored to people living with ME/CFS, Long COVID, and related conditions. As the population affected by infection-associated chronic conditions expands, the cost of ignoring indoor environmental risk will likely grow with it. CYNAERA’s broader framework suggests that chronic illness policy works best when biology, environment, and structural conditions are treated as one system. Mold exposure is one example of how that system fails. It is also one example of where better policy could reduce preventable harm.

Limitations and Research Needs

Environmental health research has already established strong links between damp indoor environments, mold exposure, and respiratory and inflammatory health effects. Population studies consistently show that mold contaminated buildings increase rates of asthma exacerbation, respiratory irritation, and allergic responses among occupants (Institute of Medicine 2004; Fisk et al. 2007; Mendell et al. 2011). These findings are directly relevant to individuals living with ME/CFS. Many patients with ME/CFS experience respiratory sensitivity, mast cell activation, and autonomic instability, all of which can be aggravated by environmental irritants. Clinicians and patient communities frequently report worsening symptoms in damp or mold contaminated environments, including increased fatigue, cognitive dysfunction, respiratory irritation, and post exertional symptom cascades.

What remains limited in the scientific literature is not the recognition that mold exposure can affect vulnerable populations, but rather the detailed characterization of how these exposures alter disease dynamics in ME/CFS. Few studies have examined whether mold exposure changes the severity of symptom flares, extends the duration of post exertional malaise, or increases the frequency of destabilization cycles over time. The limited stratification common in ME/CFS research often obscures environmentally mediated treatment effects, particularly in patients whose symptom trajectories are shaped by both biologic vulnerability and chronic housing-related exposure burden.

Future research should examine environmental exposure patterns in individuals living with infection associated chronic conditions using approaches that combine indoor environmental monitoring with longitudinal symptom tracking. Studies linking environmental measurements with clinical outcomes such as flare duration, PEM severity, and recovery time could help clarify how environmental instability interacts with chronic illness physiology. Understanding these relationships will be important not only for clinical management but also for housing policy and environmental health protections for medically vulnerable populations.

Environmental Health Evidence in Mold and Housing Litigation

Environmental health research on damp indoor environments and mold exposure has been frequently discussed in housing disputes, building defect cases, and indoor air quality litigation. Courts evaluating scientific testimony in these cases generally apply one of two evidentiary standards: the Frye standard or the Daubert standard. Under the Frye standard, which remains in use in several U.S. jurisdictions, scientific testimony must be based on principles that are generally accepted within the relevant scientific community. Consensus reports produced by major public health institutions such as the National Academies of Sciences and the World Health Organization are often cited in this context because they synthesize large bodies of peer-reviewed environmental health research (Institute of Medicine 2004; World Health Organization 2009).

Under the Daubert standard, used in federal courts and many state courts, judges evaluate whether expert testimony is based on reliable scientific methods. Factors may include whether the theory has been tested, whether it has been subject to peer review, whether there are known error rates, and whether the methodology is widely accepted within the scientific community. Research on damp indoor environments and mold exposure satisfies many of these criteria. Large epidemiological reviews have documented consistent associations between damp indoor environments and respiratory symptoms, asthma exacerbation, allergic responses, and other adverse health outcomes among building occupants (Fisk et al. 2007; Mendell et al. 2011). These findings have been reproduced across residential housing, schools, and occupational environments affected by moisture intrusion.

Courts have also previously admitted expert testimony regarding mold exposure and health effects in residential building disputes. For example, in Mondelli v. Kendel Homes Corp. (Nebraska 2001), the court allowed expert testimony linking mold exposure to respiratory illness in the context of a construction defect claim. Similar cases have considered environmental health evidence regarding indoor mold contamination and building moisture failures. The present analysis does not introduce a novel disease theory. Instead, it synthesizes existing environmental health literature with population prevalence modeling related to ME/CFS and infection-associated chronic conditions. The biological mechanisms described in this paper, including inflammatory responses to environmental irritants and symptom destabilization in medically vulnerable populations are consistent with established environmental health research. Accordingly, the framework presented here should be understood as an application of widely recognized environmental health principles to chronic illness populations rather than the proposal of a new or untested scientific hypothesis.

Translational Application: Detecting Environmentally Constrained Recovery

This framework also points toward a larger clinical application: the ability to identify when a patient’s home environment may be actively suppressing recovery. In ME/CFS, where symptom burden is shaped by biologic fragility, multi-trigger reactivity, and fluctuating response to treatment, mold exposure may not act alone. It may interact with food sensitivity, dust and pollen reactivity, medication intolerance, mast cell activation, autonomic instability, and post-exertional worsening to create a persistent state of recovery interference. A future modeling system built on this logic could integrate longitudinal symptom data, treatment history, laboratory trends, electronic health records, housing conditions, and environmental exposure signals to estimate whether indoor mold burden is plausibly contributing to flare recurrence, treatment plateauing, or slower-than-expected functional improvement.

Such a tool would not replace clinical judgment or serve as a stand-alone diagnostic test. Its value would lie in structured inference: identifying when environmentally constrained recovery is a credible explanation for persistent instability, incomplete therapeutic gain, or apparent treatment resistance. That capability has implications not only for clinical care, but also for housing intervention, disability assessment, utilization forecasting, and public health planning.

Conclusion

Mold exposure is not best understood as an isolated indoor air problem. For people living with ME/CFS and related infection-associated chronic conditions, it may function as a destabilizing environmental force that increases flare frequency, deepens disability burden, and raises both individual and system-level costs. As this paper argues, the significance of mold is not limited to symptom aggravation alone. It may also suppress treatment response, lower the ceiling of achievable recovery, and make otherwise reasonable therapies appear less effective than they truly are under stable environmental conditions.

The simulated 12-week LDN response model presented here helps clarify that point. Under matched treatment conditions, patients living in mold-exposed environments reached earlier and lower response plateaus than comparable patients in non-mold settings. In this framework, environmental burden does not simply coexist with chronic illness. It actively shapes the clinical trajectory by reducing the body’s ability to convert therapeutic input into durable functional gain. That distinction matters. A patient who appears treatment resistant may in some cases be environmentally constrained.

This matters because the next era of chronic illness policy will not be won by symptom recognition alone. It will depend on whether health systems, housing systems, and public health systems learn to recognize the same reality at the same time: the body does not heal in isolation from its environment. In that sense, mold is not a side issue. It is part of the terrain. It reveals how structural conditions, indoor environments, and biologic vulnerability interact to shape whether patients remain trapped in instability or move toward greater safety and functional recovery.

For CYNAERA, that is the larger point. Infection-associated chronic conditions are not only biomedical events. They are environmentally mediated, socially patterned, and economically consequential disease states. Understanding mold exposure through that lens moves the conversation from anecdote to infrastructure, and from symptom management to systems intelligence. It also makes clear that improving outcomes will require more than clinical care alone. It will require environments that allow treatment to work.

CYNAERA Frameworks Referenced in This Paper 

This paper draws on a defined subset of CYNAERA white papers that establish the theoretical, methodological, and operational foundations for Minimum Viable Data, nuance aware LLMs. The references below are deeper insights on the models, definitions, and outcomes presented here.

• Why Drug Approval For ME/CFS Was Always A Setup

• MECFS Phenotyping 

• SPARC Smart Study Stratification

• Best Practices for a MECFS Study

• CYNAERA Complex Chronic Illness Patient Stratification

• AI ME/CFS Individual Regimen Simulation 

• ME/CFS Treatment Archetypes

• MECFS Diagnostic Fingerprint 

• Demographics of ME/CFS in the United States

• Socioeconomic Impact of MECFS

• Undercounted from Kabul to Kansas: The Hidden Men of IACC

• The Pathophysiology of Infection-Associated Chronic Conditions

• CYNAERA’s VitalGuard™ Environmental Flare Risk Engine

• The Hidden Public Health Cost of AI Data Centers

•  Environmental Triggers of ME/CFS Flares

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

​Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including Pathos™, VitalGuard™, CRATE™, SymCas™, TrialSim™, and BRAGS™, are protected under U.S. Provisional Patent Application No. 63/909,951.

Licensing and Integration

CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.

Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.

About the Author 

Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, Board Member at Solve M.E., and collaborator with Selin Lab for t cell research at the University of Massachusetts.

Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.

Through CYNAERA, she develops modular AI platforms, including the IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.

Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.

References

1. Agency for Toxic Substances and Disease Registry (ATSDR). 2020. Toxicological Profile for Polycyclic Aromatic Hydrocarbons (PAHs). U.S. Department of Health and Human Services.

2. Al-Aly, Z., Xie, Y., & Bowe, B. 2021. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594:259–264.

3. Boström, C. E., Gerde, P., Hanberg, A., Jernström, B., Johansson, C., Kyrklund, T., Rannug, A., Törnqvist, M., Victorin, K., & Westerholm, R. 2002. Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air. Environmental Health Perspectives 110(Suppl 3):451–488.

4. Chen, T. M., Gokhale, J., Shofer, S., & Kuschner, W. G. 2007. Outdoor air pollution: nitrogen dioxide, sulfur dioxide, and carbon monoxide health effects. American Journal of the Medical Sciences 333(4):249–256.

5. Chu, L., Valencia, I., Garvert, D., & Montoya, J. G. 2019. Onset patterns and course of myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Pediatrics 7:12.

6. Ciencewicki, J., & Jaspers, I. 2007. Air pollution and respiratory viral infection. Inhalation Toxicology 19(14):1135–1146.

7. Collin, S. M., Crawley, E., May, M. T., Sterne, J. A., & Hollingworth, W. 2011. The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study. BMC Health Services Research 11:217.

8. Drzazga, A., et al. 2021. Volatile organic compounds and their impact on human health. International Journal of Environmental Research and Public Health 18(17):9166.

9. Fisk, W. J., Lei-Gomez, Q., & Mendell, M. J. 2007. Meta-analyses of the associations of respiratory health effects with dampness and mold in homes. Indoor Air 17(4):284–296.

10. Gawda, A., Majka, G., Nowak, B., & Marcinkiewicz, J. 2018. Air pollution, oxidative stress, and exacerbation of autoimmune diseases. Central European Journal of Immunology 43(3):305–312.

11. Hanna, A. F., Yeatts, K. B., & Stewart, J. 2021. Indoor volatile organic compounds and their health impacts. Environmental Research 196:110851.

12. Hollingsworth, J. W., Kleeberger, S. R., & Foster, W. M. 2007. Ozone and pulmonary innate immunity. Proceedings of the American Thoracic Society 4(3):240–246.

13. Institute of Medicine. 2004. Damp Indoor Spaces and Health. Washington, DC: National Academies Press.

14. International Agency for Research on Cancer (IARC). 2010. Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Non-Heterocyclic Polycyclic Aromatic Hydrocarbons and Some Related Exposures.

15. Intergovernmental Panel on Climate Change (IPCC). 2023. Sixth Assessment Report: Climate Change 2023.

16. Jason, L. A., Benton, M. C., Valentine, L., Johnson, A., & Torres-Harding, S. 2008. The economic impact of ME/CFS: individual and societal costs. Dynamic Medicine 7:6.

17. Jason, L. A., Sunnquist, M., Brown, A., Reed, J., & Newton, J. L. 2015. Fatigue scales and chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome Research.

18. Jerrett, M., Burnett, R. T., Pope, C. A., et al. 2009. Long-term ozone exposure and mortality. New England Journal of Medicine 360:1085–1095.

19. Kim, K. H., Jahan, S. A., Kabir, E., & Brown, R. J. 2013. A review of airborne polycyclic aromatic hydrocarbons and their human health effects. Environment International 60:71–80.

20. Komaroff, A. L., & Bateman, L. 2021. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Frontiers in Medicine 7:606824.

21. Komaroff, A. L., & Lipkin, W. I. 2021. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of post-acute COVID-19 syndrome. Trends in Molecular Medicine 27(9):895–906.

22. Landrigan, P. J., Fuller, R., Acosta, N., et al. 2018. The Lancet Commission on pollution and health. The Lancet 391:462–512.

23. Mendell, M. J., Mirer, A. G., Cheung, K., Tong, M., & Douwes, J. 2011. Respiratory and allergic health effects of dampness, mold, and dampness-related agents. Environmental Health Perspectives 119(6):748–756.

24. Nacul, L., Lacerda, E., Campion, P., et al. 2020. The functional status and well-being of people with ME/CFS. BMC Public Health 20:186.

25. National Academies of Sciences, Engineering, and Medicine. 2015. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.

26. National Academies of Sciences, Engineering, and Medicine. 2024. Long-Term Health Effects of COVID-19 and Implications for Chronic Disease.

27. Pope, C. A., Burnett, R. T., Turner, M. C., et al. 2016. Long-term exposure to fine particulate matter and mortality. Environmental Health Perspectives 124(5):637–645.

28. Schraufnagel, D. E., Balmes, J. R., Cowl, C. T., et al. 2019. Air pollution and noncommunicable diseases. Chest 155(2):409–416.

29. World Health Organization. 2009. WHO Guidelines for Indoor Air Quality: Dampness and Mould.

30. World Health Organization. 2022. Global Air Quality Guidelines.

31. Xie, Y., Bowe, B., & Al-Aly, Z. 2022. Burdens of post-acute sequelae of COVID-19. Nature Medicine 28:583–590.

32. U.S. Environmental Protection Agency. 2022. Integrated Science Assessment for Nitrogen Oxides.

33. U.S. Environmental Protection Agency. 2023. Integrated Science Assessment for Particulate Matter.